ombitsavir, paritaprevir, retrovir, and dasabuvir (Viekira Pak®, Viekira XR®)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of chronic hepatitis C, genotype 1a and 1b without cirrhosis or with compensated cirrhosis

All of the following must be met as a condition for coverage:

  • Patient must have compensated liver disease by fibroscan ultrasound or biopsy, documenting stage 2, stage 3, or stage 4
  • Resistance testing must be included with the prior authorization request for genotype 1.
    • Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence and poses a substantial problem to clinicians trying to re-treat patients who have failed available interferon-free treatments.
  • Trial and failure of preferred agent(s) Epclusa, Harvoni, Vosevi

This Medication is Not Approvable for the following condition(s):

  • Patients with Stage 0 or stage 1 fibrosis
  • Any condition not listed above as an approved indication

Fibrosis

  • Stage 0 or 1 none or mild peri-portal fibrosis – not approvable
  • Stage 2 peri-portal fibrosis with/without extension and portal-portal bridging – approvable
  • Stage 3 portal-central bridges but no nodular formation - approvable
  • Stage 4 definite cirrhosis – approvable

Dosing:

  • Immediate-release (Viekira Pak):  Ombitasvir/paritaprevir/ritonavir tablet:  2 tablets every morning.  Dasabuvir tablet:  1 tablet twice daily.
  • Extended-release:  3 tablets once daily

Duration of therapy:

  • Genotype 1a, 12 weeks (without cirrhosis); 24 weeks (with compensated cirrhosis [Child-Pugh class A]).  Based on prior treatment history, some patients with compensated cirrhosis may be considered for a duration of therapy of 12 weeks.
  • Genotype 1b, 12 weeks (with or without compensated cirrhosis [Child-Pugh class A])
  • Genotype 1, unknown subtype or mixed infection:  12 weeks (without cirrhosis); 24 weeks (with compensated cirrhosis [Child-Pugh class A]).  Based on prior treatment history, some patients with compensated cirrhosis may be considered for a duration of therapy of 12 weeks.
  • Liver transplant recipients (Metavir fibrosis score 2 or less), regardless of genotype 1 subtype:  24 weeks.

Concomitant therapy: 

  • Use in combination with ribavirin for patients with genotype 1a (with or without compensated cirrhosis [Child-Pugh class A]), genotype 1 subtype unknown or mixed infection, and liver transplant recipients (Metavir fibrosis score 2 or less; regardless of genotype 1 subtype).

 


 

Last review date: September 12, 2018

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone